Table 1 Characteristics of study patients according to the presence or absence of AGS symptoms with potential sources of alpha-gal and their sex
Group 1 (n = 33) | Group 2 (n = 65) | |
|---|---|---|
Sociodemographic Data | ||
Sex, n(%) | ||
Women Men | 3 (9.1) 30 (90.9) | 40 (65.5) 25 (38.5) |
Age (years), mean (SD) Women Men | 46.91 (13.24) 36.33 (6.60) 47.97 (13.27) | 47.65 (14.84) 45.23 (14.36) 51.52 (14.77) |
Tick bites, n (%) Women Men | 27 (81.8) 2 (66.7) 25 (83.3) | 18 (27.7) 11 (27.5) 7 (28.0) |
Outdoor activities, n (%) Women Men | 33 (100.0) 30 (100.0) 3 (100.0) | 49 (75.4) 28 (70.0) 21 (84.0) |
Clinical Features | ||
Symptoms with potential sources of alpha-gal, n (%) Women Men | 33 (100.0) 3 (9.1) 30 (90.9) | 0 (0.0) 0 (0.0) 0 (0.0) |
Tolerance to potential sources of alpha-gal, n (%) Women Men | 0 (0.0) 0 (0.0) 0 (0.0) | 65 (100.0) 40 (65.5) 25 (38.5) |
Immunological Data | ||
Total IgE (kUA/L), mean (SD) Women Men | 495.99 (747.65) 308.73 (363.37) 514.72 (773.18) | 334.10 (601.85) 244.54 (474.37) 477.39 (740.53) |
sIgE to alpha-gal (kUA/L), mean (SD) Women Men | 31.70 (36.06) 0.81(0.35) 9.29 (44.45) | 0.28 (1.41) 0.03 (0.12) 0.67 (2.21) |
sIgE to alpha-gal ≥ 0.1 kUA/L, n (%) Women Men | 32 (98.0) 2 (6.1) 30 (90.9) | 7 (10.8) 2 (3.1) 5 (7.7) |
sIgE to alpha-gal ≥ 2.0 kUA/L, n (%) Women Men | 26 (78.79) 0 (0.0) 26 (86.67) | 2 (3.08) 0 (0.0) 2 (8.00) |